Skip to main content

Table 3 Patients characteristics by ROC cutoff points in PRAME gene expression

From: Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients

Characteristics PRAME < 2.609 (n=27) PRAME > 2.609 (n=15) p value
Age (years) 35 (5–88) 41 (1–65) 0.4212
Gender: M/F 20/7 (74.07%/25.9%) 9/6 (60%/40%) 0.4880
WBC × 103/L 34.3 (12–100) 30.4 (3.7–99.9) 0.5038
Lymphocyte % 65.7 (1.6–99.9) 67.1 (1.7–99.9) 0.4155
Hb (g/dL) 9.8 (5.9–15.3) 10.4 (6.6–15) 0.4157
ESR (mm/h) 68 (15–140) 78.5 (39–140) 0.4345
Total protein (g/dL) 6.9 (4.8–8.3) 6.9 (5.4–8.2) 0.3262
Albumin (g/dL) 3.9 (2.5–4.5) 3.6 (2.7–4.8) 0.2626
Globulin (g/dL) 3.2 (2.3–4.8) 3.3 (2.4–4.2) 0.9818
A/G ratio 1.1(0.7–1.8) 1.16 (0.7–1.8) 0.6092
Bilirubin direct 0.4 (0–2.4) 0.6 (0–2.2) 0.6246
Bilirubin indirect 0.43 (0.05–3.1) 0.5 (0.1–1.4) 0.2755
Bilirubin total (mg/dL) 0.9 (0.1–3.7) 1.3 (0.2–3.7) 0.7170
SGOT (U/L) 31 (11–62) 43 (18–76) 0.2026
SGPT (U/L) 29 (6.4–118) 33 (11–72) 0.3988
ALP (U/L) 88 (55–170) 102 (56–212) 0.2185
Chloride (mg/dL) 98 (1.1–120) 107 (89–133) 0.0038**
Sodium (mg/dL) 136 (118–177) 137 (120–157) 0.3402
Potassium (mg/dL) 3.7 (2.8–6) 4.2 (3–6.3) 0.0358*
Blood urea (mg/dL) 24 (8–101) 33 (9–144) 0.3772
TLC × 109/L 23.1 (0.2–148) 33 (5.6–15) 0.7920
Creatinine 0.7 (0.2–1.7) 1.02 (0.2–2.3) 0.5621
Platelet count × 109/L 148 (2–800) 226 (10–825) 0.7229
ALC × 109/L 44.8 (1.7–97.7) 21.3 (9.1–74) 0.0216*
ANC × 109/L 57 (70–571) 170 (187–605) 0.6847
  1. Hb hemoglobulin, ESR erythrocyte sedimentation rate, SGOT Serum glutamic oxaloacetic transaminase, SGPT Serum glutamic pyruvic transaminase, ALP Alkaline phosphatases, TLC Total leucocyte count, ALC Absolute to lymphocyte ratio, NLR Neutrophil to lymphocyte ratio
  2. Highlighted values are indicating statistical significance at P < 0.05 (Where, P < 0.05*, P < 0.01**)